Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension by Mikolajczyk, T.P. et al.
The FASEB Journal • Research Communication
Role of chemokine RANTES in the regulation of
perivascular inﬂammation, T-cell accumulation, and
vascular dysfunction in hypertension
Tomasz P. Mikolajczyk,*,†,1 Ryszard Nosalski,*,†,1 Piotr Szczepaniak,*,† Klaudia Budzyn,‡
Grzegorz Osmenda,* Dominik Skiba,*,† Agnieszka Sagan,*,† Jing Wu,§ Antony Vinh,‡
Paul J. Marvar,{ Bartlomiej Guzik,* Jakub Podolec,* Grant Drummond,‡ Heinrich E. Lob,k
David G. Harrison,§ and Tomasz J. Guzik*,†,2
*Department of Internal Medicine, Jagiellonian University, Cracow, Poland; †British Heart Foundation
Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
United Kingdom; ‡Department of Pharmacology, Monash University, Melbourne, Victoria, Australia;
§Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine,
Nashville, Tennessee, USA; {Department of Pharmacology and Physiology, George Washington
University, Washington, D.C., USA; and ║Department of Biomedical Sciences, Cornell University, Ithaca,
New York, USA
ABSTRACT Recent studieshave emphasized the roleof
perivascular inﬂammation in cardiovascular disease. We
studied mechanisms of perivascular leukocyte inﬁltration
in angiotensin II (Ang II)-induced hypertension and their
links to vascular dysfunction. Chronic Ang II infusion in
mice increased immune cell content of T cells (2556 130
to 1664 6 349 cells/mg; P < 0.01), M1 and M2 macro-
phages, and dendritic cells in perivascular adipose tissue.
In particular, the content of T lymphocytes bearing CC
chemokine receptor (CCR) 1, CCR3, and CCR5 receptors
for RANTES chemokine was increased by Ang II (CCR1,
15.6 6 1.5% vs. 31 6 5%; P < 0.01). Hypertension was
associated with an increase in perivascular adipose tissue
expression of the chemokine RANTES (relative quantiﬁ-
cation, 1.26 0.2 vs. 3.56 1.1; P < 0.05), which induced
T-cell chemotaxis and vascular accumulation of T cells
expressing the chemokine receptors CCR1, CCR3, and
CCR5. Mechanistically, RANTES2/2 knockout protected
against vascular leukocyte, and in particular T lymphocyte
inﬁltration (26 6 5% in wild type Ang II vs. 15 6 4% in
RANTES2/2), which was associated with protection from
endothelial dysfunction inducedbyAng II. This effect was
linked with diminished inﬁltration of IFN-g-producing
CD8+ and double-negative CD3+CD42CD82 T cells in
perivascular space and reduced vascular oxidative stress
while FoxP3+ T-regulatory cells were unaltered. IFN-g ex
vivo caused signiﬁcant endothelial dysfunction, which was
reduced by superoxide anion scavenging. In a human co-
hort, a signiﬁcant inverse correlation was observed between
circulating RANTES levels as a biomarker and vascular
functionmeasured asﬂow-mediated dilatation (R =20.3,
P < 0.01) or endothelial injury marker von Willebrand
factor (R = +0.3; P < 0.01). Thus, chemokine RANTES is
important in the regulation of vascular dysfunction
through modulation of perivascular inﬂammation.—
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Traditionally, adipose tissue (AT) has been considered a
site for energy storage; however, there is increasing interest
in the role of AT in inﬂammation (1–3). Cells of the innate
and adaptive immune system, such as macrophages
and lymphocytes, accumulate in visceral AT butminimally
in subcutaneousAT (4). Visceral AThas oftenbeen viewed
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as a homogenous; however, AT adjacent to large- and
medium-size vessels—that is, perivascular AT (pVAT)—
seems to represent a specialized compartment fromwhich
releaseof fatty acids, adipokines, andothermediators exert
both beneﬁcial and untoward effects on the adjacent ves-
sels (5–7). Alterations of pVAT structure and function in
genetically hypertensive rats have been implicated in al-
tering vasomotor tone (6), but the role of pVAT in regu-
lation of vascular function and vascular inﬂammation in
hypertension remains unclear.
Recently we found that hypertensive stimuli such as angio-
tensin II (Ang II) and excess salt promote inﬁltration of
leukocytes, including T cells, into pVAT (8). Subsequent
studieshave shown thatT-cell (9–11),monocyte(12), andNK-
cell (13) activation and recruitment into target organs is very
important in the pathogenesis of hypertension (8, 14, 15) and
in target organ damage (16–18). Likewise, T cells accumulate
in pVAT and adventitia of hypercholesterolemic mice (19).
While these studiesemphasize the roleof thepVATinvascular
disease, themechanisms involved in homing of inﬂammatory
cells topVATareundeterminedinhypertension. Interestingly,
a largeproportionof these cells bearRANTESCCchemokine
receptor (CCR) 5 (8). RANTES, also referred to as CC che-
mokine ligand 5 (CCL5), is an important chemoattractant for
inﬂammatory cells that has been implicated in the pathogen-
esisofatherosclerosis(20)andispresent inATofbothhumans
and mice (4). RANTES can be produced by resident cells of
the vessel and AT, and Ang II added in vitro increases its ex-
pression in arteriolar and venular endothelium (21). We hy-
pothesized that RANTES plays a crucial role in the genesis of
perivascular inﬂammation and can therefore affect the devel-
opment of vascular dysfunction in hypertension.
In the present study, using RANTES2/2mice and wild-
type (WT) controls, we identify a novel role of RANTES in
regulation of vascular dysfunction in Ang II–induced hy-
pertension. These effects of RANTES are particularly re-
lated tomodulationof recruitmentof IFN-g toperivascular
AT and, importantly, are independent of blood pressure
changes. Finally, we demonstrate that pharmacologic
modulation of this pathway can protect from vascular dys-
function development in hypertension.
MATERIALS AND METHODS
Animals
Male C57BL/6 (n = 58) and RANTES2/2 (n = 24) mice were
obtained from The Jackson Laboratory (Bar Harbor, ME, USA).
Twelve-week-oldmice (bodymass 276 3 g) underwent either sham
or Ang II (490 ng/min/kg s.c.) treatment for 14 d via a surgically
implanted osmoticminipump (AlzetModel 2002; Alzet, Cupertino,
CA, USA). Sham treatment involved infusion of the vehicle for Ang
II. During treatment, all mice underwent noninvasive blood pres-
sure measurement by tail cuff plethysmography after a period of
training before commencement of the treatment protocol. For in-
vasive measurements of blood pressure, radiotelemetry units were
inserted 7 to 10dbeforeAng II infusion, as previously described (8).
The Institutional Animal Care and Use Committees at Jagiellonian
University and at EmoryUniversity approved the protocols we used.
Met-RANTES treatment
Both sham- and Ang II–treated C57BL/6 mice also received the
RANTES receptor antagonist met-RANTES (50 mg/kg i.p.; gift
from A. Proudfoot, Merck Serono, Darmstadt, Germany) or ve-
hicle (sterile PBS) every third day during the 14 d treatment pe-
riod. Met-RANTES was ﬁrst dissolved in sterile water to a
concentration of 4 mg/L and was subsequently diluted in sterile
PBS for in vivo use.
Measurement of mRNA expression
Tissue levels of mRNA of various chemokines and cytokines were
quantiﬁed by real-time PCR with commercially available assays
(TaqMan; Applied Biosystems, Foster City, CA, USA). Data were
normalized to levels of 18SmRNA, and relative quantiﬁcationwas
calculated as 22DDCt.
Immunohistochemical analysis of RANTES localization
After euthanasia, a cannula was placed in the right ventricle and
mice were perfused with saline followed by 10% formaldehyde.
Aortic tissue was embedded in parafﬁn. An anti-mouse/rat CCL5
(RANTES) antibodies (1:100, overnight, 4°C; eBioscience, San
Diego, CA, USA) or anti-CCL5 (189841; Abcam) and staining
was visualized using the Dako LSAB+ System HRP kit (Dako,
Glostrup, Denmark) according to the manufacturer’s protocol.
Studies were performed at d 7 and 14 of Ang II infusion.
Measurements of vascular reactivity and superoxide
production in aortic segments
Relaxation to the endothelium-dependent and -independent vaso-
dilators acetylcholine (ACh) and sodium nitroprusside was mea-
sured in isolated 3 to 4mm segments of aorta in organ chambers as
previously described (8). In some experiments, aortic rings were
preincubated for 24 h in RPMI containing 50 mg/ml IFN-g or
control buffer to assess the direct effects of this cytokine on endo-
thelial function. Polyethylene glycol superoxide dismutase (PEG-
SOD; 500 IU/ml) was used to dissect the role of superoxide in
endothelial dysfunction. Aortic superoxide production was mea-
sured by quantifying formation of 2-hydroxyethidium from dihy-
droethidium (25 mM) by HPLC. This product speciﬁcally reﬂects
the reaction of superoxide anion with dihydroethidium and has
been validated previously (8). In validating studies vascular seg-
mentswerepreincubatedwith100U/mlPEG-SOD,which inhibited
806 15% of Ang II–dependent increase in detected superoxide.
Analysis of leukocytes in tissues
pVAT was isolated from thoracic and abdominal aorta. This re-
gion of AT is invariably present on the anterior surface of the
aorta and adheres when the aorta is removed from the mouse.
Epididymal fat pads were used as representative of visceral fat. Sub-
cutaneous fat was obtained from the inguinal fossae and the sub-
scapular region. For analysis of cells in fat, AT was digested using
collagenase type XI (125 U/ml), collagenase type IS (450 U/ml),
and hyaluronidase IV-S (60 U/ml) that had been dissolved in
PBS containing calcium and magnesium for 20 min at 37°C,
with regular agitation. The digested tissue was then passed
through a 70 mm sterile cell strainer (Falcon; BD Biosciences,
San Jose, CA, USA) to yield a single-cell suspension. Cells were
washed and resuspended in ﬂuorescence-activated cell sorting
buffer, counted, and stained, usingmulticolorﬂow cytometry as
previously described (8, 19, 22), using a BD FACSCanto II ﬂow
cytometer with DIVA software (BD Biosciences). Macrophage
subpopulations were deﬁned in F4/80+CD11b population by
expression of CD11c and CD206 as previously described (23).
Intracellular staining was performed as previously described
(24).Dead cells were eliminated fromanalysis using 7-AAD (BD
Biosciences). For each experiment, we performedﬂuorescence
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minus one controls for each ﬂuorophore to establish gates. In
selected experiments, we conﬁrmed accuracy of the ﬂuorescence
minus one gating strategy using isotype controls. Data were ana-
lyzed by FlowJo 8.8.1 software (FlowJo, Ashland, OR, USA).
Chemotaxis assay
Bloodwasobtained fromeither sham-orAngII–infusedmiceand
total peripheral blood mononuclear cells were isolated by a
standarddensity gradientwith LSM1077Lymphocyte Separation
Medium (PAA Laboratories, Pasching, Austria). Either T cells or
B cells were isolated from peripheral bloodmononuclear cells by
negative selection. Cell purity was conﬁrmed to be $96%. After
separation, the lymphocytes were resuspended in RPMI 1640
(Gibco, Carlsbad, CA, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco), 2 mM/ml L-glutamine,
and 50 mg/ml gentamicin (Sigma-Aldrich, St. Louis, MO, USA).
Cells (23105)were added to theupper chamberof a 24-transwell
apparatus (6.5 mm diameter, 5 mm pore size; Costar 3421) and
incubated for 2 h at 37°C in 5% CO2. Recombinant mouse
CCL5/RANTES (10 ng/ml; R&D Systems, Minneapolis, MN,
USA) or supernatant (conditionedmedium) from an 18 h organ
culture of pVAT (diluted 1:50) was placed in the lower chamber.
The optimal concentration of RANTES was determined in pre-
liminary experiments. In a subset of experiments, conditioned
medium from pVAT–Ang II cultures was preincubated with
0.5 mg/ml anti-RANTES antibody (clone 53405; R&D Systems)
chemotaxis was assessed. The percentage of cells thatmigrated to
the lower chamber was determined by ﬂow cytometry as de-
scribed above.
Endothelial function studies in humans
Vascular function was measured in 129 subjects with type 2 di-
abetes. The clinical characteristics of the population are shown in
Table 1. Major clinical risk factors were categorized as follows:
hypercholesterolemia (total plasma cholesterol .4.8 mM or
use of cholesterol-lowering medication); smoking (current
or within last 6 mo); diabetes (fasting glucose .5.5 mM or
current treatment with insulin or oral hypoglycemic agents); hy-
pertension (blood pressure .140/90 mmHg or current treat-
ment with antihypertensive agents), and overweight and obesity
(bodymass index.25 kg/m2). Someof these subjects havebeen
described in a prior publication (24). Flow-mediated dilatation
(FMD) was used as a measure of endothelial function, as de-
scribed in detail elsewhere (25). Images were analyzed by Vas-
cular Tools 5 software by 2 independent blinded observers. Von
Willebrand factor (vWF) was measured using sandwich immu-
noassay utilizing an anti-human vWF antibody (Dako) and ex-
pressed as percentage of reference sample (25). Serum RANTES
levelsweredeterminedusingaquantitativeELISA(CCL5/RANTES
Quantikine ELISA kit; R&D Systems). The Jagiellonian Univer-
sity ethics committee approved all human studies. All subjects
provided written informed consent before the study.
Statistical analysis
For comparison of 2 groups, unpaired 2-tailed Student’s t tests
were used. For comparison of 3 ormore independent groups, 1-way
ANOVA was used with a Student-Newman-Keuls post hoc test. For
comparison of the effects of Ang II on parameters in different
groups of mice, we used 2-way ANOVA with a Bonferroni post hoc
test. For comparisons of vascular function in organ chamber ex-
periments, repeatedmeasures ANOVAwas used. The relationship
between RANTES and vWF levels with FMD and nitroglycerin-
mediated dilatationwere analyzed by Spearman’s correlation tests.
Values of P, 0.05 were considered signiﬁcant.
RESULTS
Leukocyte content in pVAT and effect of Ang II
Leukocytes represented 2% of the vascular stromal frac-
tion of pVAT in sham-treated mice. Ang II infusion sig-
niﬁcantly increased both the percentage and absolute
quantity of leukocytes in pVAT (Fig. 1A, B). Using anti-
bodies against speciﬁc markers for T cells (CD3), B cells
(CD19), macrophages (I-Ab/CD11b), and dendritic cells
(DCs; CD11c/I-Ab), we found that pVAT contained all of
these cell types (Fig. 1C). Ang II infusion markedly in-
creased the number of T cells, macrophages, and DCs in
pVAT (Fig. 1C) while not affecting the content of these in
visceral or subcutaneous fat. Although there was a modest
increase in B cells in the pVAT in response to Ang II, this
was not statistically signiﬁcant (Fig. 1C). Thus, macro-
phages, DCs, and T cells are themost prevalent leukocytes
in the pVAT of Ang II hypertensive mice. Ang II caused
greatest increase of T cells in pVAT percentage-wise (156
2 to 246 5%; P, 0.05).
Role of RANTES and its receptors in AT
T-cell recruitment
We next focused on understanding the mechanisms re-
sponsible for T-cell accumulation in pVAT. Ang II infusion
increased the percentage of total T cells expressing the
RANTES receptors CCR1, CCR3, and CCR5 in pVAT (Fig.
1D and Supplemental Fig. S1A), but not in visceral fat
(Supplemental Fig. S2). In keeping with the attraction of
T cells bearing these surface receptors, Ang II increased
RANTESmRNA in the perivascular fat already at d 7 of Ang
TABLE 1. Clinical characteristics of high-cardiovascular-risk study
cohort
Characteristic Patient cohort
No. of patients 129
Age (y) 56.6 6 6.3
Sex (M:F) 64:65
Risk factors
Current smoking 29 (22%)
Hypertension 115 (89%)
Diabetes 129 (100%)
Hypercholesterolemia 90 (70%)
BMI (kg/m2) 32.5 6 5.6
Cholesterol (mM) 5.4 6 1.6
CAD 65 (50%)
Cardiovascular medications
Aspirin 70 (54%)
Angiotensin-converting enzyme inhibitor 99 (77%)
b-Blocker 48 (37%)
Statin 62 (48%)
Calcium channel blocker 30 (23%)
Insulin 68 (52%)
Oral hypoglycemic drugs 83 (64%)
Data are presented as means6 SD or n (%). CAD, coronary artery
disease; BMI, body mass index.
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Figure 1. Leukocyte inﬁltration, chemokine receptors, and RANTES expression in pVAT during Ang II–dependent hypertension.
Hypertension was induced by chronic 14 d Ang II infusion by osmotic minipump (490 ng/min/kg), and AT was obtained from
periaortic fat pad (pVAT) and epididymal AT (visceral AT). A) Representative ﬂow cytometric analysis of major leukocyte
subpopulations in vascular stromal fraction isolated from periaortic AT of sham- and Ang II–infused mice. B) Effect of Ang II
(continued on next page)
1990 Vol. 30 May 2016 MIKOLAJCZYK ET AL.The FASEB Journal x www.fasebj.org
II infusion while not changing RANTES mRNA in visceral
AT (Fig. 1E). Moreover, at d 14 of Ang II infusion, when
vascularpathology is fully developed in thismodel,RANTES
expression was further up-regulated while no increase was
observed in either visceral AT or brown AT (BAT). Immu-
nohistochemical staining conﬁrmed that RANTES protein
was present in perivascular fat and adventitia after Ang II
infusion at both d 7 (Fig. 1E) and d 14 (Fig. 1F). RANTES
can be produced by both T cells and by resident cells within
tissues; however, Ang II also increases RANTES mRNA in
the pVAT of RAG-12/2 mice to an extent similar to that
observedWTmice (3.16 0.5 fold;P, 0.01), indicating that
resident cells rather than lymphocytes are themajor source
of this chemokine in response to Ang II.
To gain additional insight into the role of RANTES, we
performed chemotaxis assays of lymphocytes from sham-
and Ang II–treated mice toward soluble RANTES in a
Boyden chamber. As is evident in Fig. 2A, T cells, but not
Bcells, fromAngII–infusedmiceweremoreavidly attracted
to RANTES than T cells from sham-infused animals. This
was true for both CD4 and CD8 cells (Fig. 2B). In further
studies, we placed conditionedmedium from organoid
cultures of pVAT from sham- and Ang II–treated mice in
the lower portion of a Boyden chamber and examined
migration of T cells from Ang II–treatedmice. There was
minimal migration of T cells toward the conditioned
medium of pVAT from sham-infused mice (Fig. 2C);
however, CD4+, CD8+, and double-negative CD3+CD42
CD82 T cells were stimulated to migrate toward the
conditionedmediumof pVAT fromAng II–treatedmice
(Fig. 2D and Supplemental Fig. S1B, respectively). Im-
portantly, when conditionedmediawas preincubatedwith
0.5 mg/ml anti-RANTES antibody (clone 53405; R&D
Systems), T-cell chemotaxis toward pVAT from Ang II–
infused mice was signiﬁcantly reduced (Fig. 2E).
Role of RANTES in vascular dysfunction and blood
pressure elevation in response to Ang II
RANTES shows signiﬁcant functional effects in the vascula-
ture, as the vasodilatationevokedbyAChwas impaired inWT
mice but not in RANTES2/2mice that had received Ang II
(Fig. 3A). Endothelium-independent responses to sodium
nitroprusside were not altered by Ang II in either WT or
RANTES2/2mice(Fig.3B).Vascular superoxideproduction
didnotdifferbetweenWTandRANTES2/2miceatbaseline,
but lack of RANTES was associated with abrogated Ang II–
induced increase in vascular superoxide (Fig. 3C). We next
examinedthehypertensiveresponse toAngII inmice lacking
RANTES using radiotelemetry (Fig. 3D). Ang II induced
approximately equivalent degrees of hypertension in WT
andRANTES2/2mice(Fig. 3D).Ang II-inducedhypertension
was associated with increased sensitivity to noradrenaline
induced vasoconstriction and this effect was were unaltered
in RANTES2/2mice (Supplemental Fig. S3)
To validate links between RANTES and endothelial
function in humans, we examined the relationship be-
tween FMD and serum level of RANTES in a cohort of
subjects withmetabolic syndromeandother risk factors for
coronary disease as described in Table 1. A statistically
signiﬁcant inverse relationship between FMD and RANTES
was observed (Fig. 3E), while there was no relationship be-
tween the brachial artery response to nitroglycerin and
RANTES (Fig. 3F). In line with this, levels of vWF, an in-
dependent measure of endothelial dysfunction, also posi-
tively correlated with levels of RANTES (Fig. 3G).
Role of RANTES in modulating perivascular
inﬂammation in Ang II hypertension
While the inﬁltration of total leukocytes in pVAT of
RANTES2/2micewasmodestly reduced compared to that
of WT mice, the inﬁltration of T cells was 50% less in
RANTES2/2 mice compared to WT mice (Fig. 4A, B).
Interestingly, RANTES deﬁciency was also associated with
decreased pVAT macrophage content, but this effect was
less pronounced (Fig. 4C). Within the F4/80+CD11b+
macrophages,bothCD11c+CD2062 (correspondingmainly
toM1polarization) andCD11c2CD206+ (corresponding to
M2polarization)(Fig.4E)were signiﬁcantly increased in the
pVAT by Ang II infusion (Fig. 4F). Both of these subpopu-
lations in the pVAT were decreased in hypertensive
RANTES2/2 mice, although this RANTES-related effect
was particularly pronounced in relation to CD11c2CD206+
cells (Fig. 4F).
RANTES’effectonrelativecontentofTcellswas,however,
morepronounced thanonother leukocyte subsets (Fig. 4D).
Thus, in Ang II–dependent hypertension, RANTES plays an
important role in homing of T cells, and particularly CCR5+
cells, to pVAT (Fig. 5A). CCR5+ cells exhibited particularly
high production of IFN-g. Accumulation of cells bearing
CCR6 remained unaffected (Fig. 5B). In line with this, re-
cruitment of T-helper (Th)17 cells (CD4 cells producing
IL-17) upon Ang II infusion, predominantly modulated
byCCR6, was not affected by RANTES2/2 (Fig. 5C). CD8+
T-cell production of IL-17 was negligible (data not shown).
RANTES is important in perivascular recruitment of
IFN-g-producing T cells, which may affect
vascular dysfunction
Because CCR5 are often expressed in IFN-g-producing
Tcells, weexamined IFN-gproductionbyTcellswithin the
pVAT. While CD4+ cells did not produce IFN-g in the
pVAT of either sham- or Ang II–infused mice, a small
number of CD8 T cells produced this cytokine at baseline,
infusion on absolute numbers of CD45+ total leukocyte content in pVAT compartment expressed per mg of tissue (n = 14). C)
Effect of Ang II infusion on content CD3+ T cells, CD19+ B cells, I-Ab+CD11b+ macrophages, and I-Ab+CD11c+ DCs in pVAT (n =
12–14 for each). D) Effect of Ang II–dependent hypertension on content of CCR1, CCR3, and CCR5+ T lymphocyte (CD3+) in
isolated pVAT (n = 6). E) Effect of 7 d Ang II–induced hypertension on mRNA expression of RANTES in pVAT and visceral AT
(n = 5), and immunostaining of aortas from sham-treated and Ang II–infused C57BL/6J mice using anti-RANTES antibody
(representative of 5 experiments). F) Effect of 14 d Ang II–induced hypertension on mRNA expression of RANTES in pVAT,
visceral AT, and BAT (n = 5) and immunostaining of aortas from sham-treated and Ang II–infused C57BL/6J mice using anti-
RANTES antibody (representative of 5 experiments).
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and this is increased in response to Ang II inWTmice. The
Ang II–dependent increase in IFN-g-producingCD8+Tcells
was not observed in RANTES2/2 mice (Fig. 5D). mRNA
expression of IFN-gwas not increased byAng II in the pVAT
of RANTES2/2mice (Fig. 5E). We have previously demon-
strated that CD3+CD42CD82 double-negative T cells were
characteristic for hypertensive vasculature. Recruitment
of CD3+CD42CD82 to pVAT is signiﬁcantly blunted in
RANTES2/2mice (Fig. 6A). Moreover, these cells can also
produce signiﬁcant amounts of IFN-g in Ang II–infusedWT
mice but not in RANTES2/2mice (Fig. 6B).
To investigate a possible role of IFN-g in causing endo-
thelial dysfunction,we incubatedaortic segmentswith IFN-g
and observed that it caused signiﬁcant endothelial dys-
function that was partially reversed by preincubation with
PEG-SOD(Fig. 5F).Thus,RANTES-dependent recruitment
of IFN-g-producing T cells may provide an important link
between perivascular inﬂammation and endothelial dys-
function in hypertension.
RANTES in perivascular recruitment of
T-regulatory cells
Because T-regulatory cells have been implicated in the path-
ogenesis of hypertension, we studied whether RANTES2/2
was associated with alterations of recruitment of these
cells into the pVAT. CD4+CD25+FoxP3+ T-regulatory con-
tent in the pVAT was very low and remained unaltered
uponAng II infusion in bothWT and RANTES2/2mice
(Supplemental Fig. S4).
Pharmacologic modulation RANTES signaling
in hypertension
To determine whether met-RANTES, a pharmacologic
inhibitor of RANTES-dependent inﬂammation, exerts
vasoprotective effects in Ang II–induced hypertension,
we treated C57Bl/6 mice intraperitoneally with met-
RANTES (50 mg/kg) every 3 d, beginning 3 d before
initiation of Ang II infusion. Intraperitoneal injection
of saline was used as a control. Met-RANTES treatment
prevented the development of endothelial dysfunction in
response to Ang II (Fig. 7A) while not signiﬁcantly affecting
blood pressure increase (tail cuff blood pressure 152 6 8
mmHg in vehicle-treated mice vs. 150 6 9 mmHg in met-
RANTES-treated mice). Similarly, the increase in vascular
superoxide production caused by Ang II was inhibited by
met-RANTES (Fig. 7B). These changes of vascular phe-
notypes were accompanied by signiﬁcant reductions of
leukocyte and T-cell recruitment into pVAT (Fig. 7C).
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Figure 2. Role of RANTES in T lymphocyte
migration in response to Ang II. Experiments
were performed in modiﬁed Boyden chamber.
A, B) Migration of T cells and their subsets and
B cells (as reference) from sham- or Ang II–infused
mice toward soluble RANTES (10 ng/ml, n = 9). C,
D) Chemotaxis of T cells and CD4+ and CD8+
T cells toward conditioned medium from pVAT
from sham- and Ang II–infused mice (n = 6
for each). E) Effects of anti-RANTES neutraliz-
ing antibody pretreatment on T-cell chemotaxis
toward pVAT conditioned medium from sham-
and Ang II–treated mice. Isotype antibody–
pretreated medium was treated as 100%. Data
are expressed as means 6 SEM.
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DISCUSSION
There is an increasing body of evidence of the role of
perivascular inﬂammation in atherosclerosis, although the
mechanisms of this link are complex and poorly un-
derstood. In the present study, we identify the role of
RANTES chemokine in mediating pVAT inﬂammation in
Ang II–induced hypertension and show possible links to
Figure 3. RANTES in Ang II–dependent hypertension and regulation of vascular dysfunction in animal model and in humans. A)
Effect of Ang II–induced hypertension on endothelium-dependent vasodilatation to ACh in aortas of WT and RANTES2/2 mice
(n = 6 for each). B) Relaxations to sodium nitroprusside as measure of non-endothelium-dependent vasodilatation (n = 6 for each).
Statistical analysis was performed by repeated measures ANOVA. C) Aortic superoxide levels measured by monitoring oxidation of
dihydroethidium to 2-hydroxyethidium using HPLC in WT and RANTES2/2mice infused for 14 d with buffer (sham) or Ang II (n =
5 each group). D) Mean daily values of invasive telemetric measurements of systolic (top left), diastolic (bottom left ), and mean
arterial (top right) blood pressure and heart rate (bottom right) at baseline and during Ang II infusion in WT and RANTES2/2mice
(n = 6). E) Correlation between serum RANTES levels and FMD in high-cardiovascular-risk cohort of 129 subjects. F) Relationship
between RANTES serum levels and non-endothelium-dependent nitroglycerin-mediated dilatation induced vasodilatation this
cohort. G) Relationship between RANTES and vWF (as biochemical marker for endothelial dysfunction) levels in serum of high-
cardiovascular-risk cohort. E–G) Statistics for these relationships presented as Spearman’s correlation tests.
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Figure 4. Role of RANTES in Ang II–dependent hypertension and T-cell perivascular inﬁltration. A) Examples of ﬂow cytometric
determination of effects of Ang II infusion on isolated pVAT (minus aorta) inﬁltration with total leukocytes (CD45+) and T cells (CD3+) in
WT and RANTES2/2 mice. B) Effect of Ang II–dependent hypertension on mean total leukocyte (CD45+ cells) and T-cell (CD3+)
content in isolated pVAT in WT and RANTES2/2mice (n = 5 each). C) Effect of Ang II–dependent hypertension on mean macrophage
(continued on next page)
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endothelial and vascular dysfunction and oxidative stress.
Ang II infusion stimulates accumulation of T cells, macro-
phages, and DCs in the pVAT but not in other visceral or
subcutaneousAT.Thisperivascular inﬂammatory response
is accompanied by increased expression of inﬂammatory
cytokines such as IFN-g or IL-17, which have been impli-
cated in the genesis of hypertension (8, 24, 26). Usingmice
lacking RANTES, we further show that at least 2 pathways
inﬁltration in pVAT (n = 5 each). D) Differences in leukocyte subpopulation composition of pVAT upon Ang II infusion in WT and
RANTES2/2mice showing notable reduction of T-cell content (n = 5 each). E) Gating strategy for detection of M2 (CD11c2CD206+)
and M1 type AT macrophages (CD11c+CD2062) within F4/80+CD11b+ cells. F) Effect of Ang II–dependent hypertension on mean M1
(left) and M2 (right) macrophage inﬁltration in pVAT upon Ang II infusion in WT and RANTES2/2 mice (n = 5 each).
Figure 5. T-cell subsets in isolated pVAT are regulated by RANTES in hypertension; links to vascular dysfunction. A, B) Flow
cytometric analyses were used to determine number of CCR5+ T cells (A) and CCR6+ T cells (B) in pVAT of sham- and Ang
II–infused mice (n = 5). C) Ang II–dependent changes in IL-17-producing CD4+ T cells in pVAT from WT and RANTES2/2mice
(n = 5). D) Ang II–dependent changes in IFN-g-producing CD8+ T cells in pVAT from WT and RANTES2/2 mice (n = 5). E)
Effect of Ang II on mRNA expression (real-time PCR) of IFN-g in pVAT from WT and RANTES2/2 mice (n = 5). F) Effects of
IFN-g (50 ng/ml) on endothelium-dependent and -independent relaxations in mouse aorta. Role of reactive oxygen species was
examined using PEG-SOD (500 IU/ml) preincubation (n = 6; P, repeated measures ANOVA).
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are operative that govern the entry of inﬂammatory cells
into the pVAT in hypertension. A RANTES-dependent
pathway promotes accumulation of macrophages and
CCR5+ and IFN-g-producing T cells into pVAT. Our ﬁnd-
ings point to reduced recruitment of IFN-g-producing
cells as a mechanism for the protection from endothelial
dysfunction and vascular oxidative stress observed in
RANTES2/2 mice. Indeed the role of IFN-g-producing
T cells has already been linked to cardiac and renal dys-
function in hypertension (27, 28). Our results are in line
with the fact that IFN-g is known to stimulate superoxide
production in vascular cells (29) and contribute to endo-
thelialdysfunction, as is alsoevident in IFN-g2/2mice(13).
While our focus was on large vessels as an indication of end-
organ damage, future studies will assess whether endothe-
lial dysfunction is also prevented in resistance vessels in the
absence of RANTES, although the lack of antihypertensive
effect could suggest otherwise.
Moreover, althoughwehavedemonstrateddirect effects
of IFN-g on endothelial function, future studies should
assess how adipokine biology is altered by perivascular in-
ﬂammation, as this could provide additional pathway for
the regulation of vascular dysfunction (7, 30).
We observed that in spite of reduced perivascular
inﬁltration of subsets of T cells and macrophages in
RANTES2/2mice, the hypertensive response to Ang II in
RANTES2/2mice is similar to that observed in WT mice.
This is important because it shows that the endothelial
dysfunction that occurs afterAng II treatment is notmerely
a consequence of increased pressure. Maintenance of
elevated blood pressure in the absence of RANTES-
dependent inﬂammation might be associated with
RANTES-independent mechanisms. These are complex
and may involve various cell types, but also other organs
such as kidneys or resistance vessels. In particular, accu-
mulation of Th17 cells, monocytes, or NK cells has been
linked to regulation of blood pressure (12, 13, 31, 32). It
may also point to the importance of kidney inﬂammation
in the regulation of blood pressure and indicate that
prevention of endothelial dysfunction alone in larger
vessels is not sufﬁcient to reduce blood pressure. More-
over, our studies show that resistance vessels’ (mesenteric
arterioles) proconstrictive properties are not affected by
RANTES2/2. Taken together with the present data, one
can hypothesize that the CCR5/RANTES axis is involved
in vascular dysfunction development independent of
initial blood pressure increase; the CCR6/IL-17 axis may
contribute to blood pressure elevation in hypertension.
Moreover, our proof-of-concept studies using met-
RANTES show that RANTES is a promising target for
the treatment of vascular dysfunction in hypertension.
A cardinal feature of any inﬂammatory process is the
coordinated expression of surface homing markers on
leukocytes and ligands for these surface receptors on the
endothelium at the affected sites. In the case of T cells, the
receptor/ligand interaction is, in some instances, highly
speciﬁc for the targeted tissue. As an example, T cells
bearing the surface marker CCR9 accumulate in the small
intestine and interact with the ligand CCL25. In contrast,
the interplay of CCR4 with CCL17 attracts inﬂammatory
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cells to the skin.UnlikeCCL25 andCCL17, RANTES is not
speciﬁcally localized in one tissue; however, its expression
pattern in response to a speciﬁc stimulus could provide
targeted homing of inﬂammatory cells. For example,
RANTES expression is speciﬁcally increased in the lungs in
the setting of atopic and nonatopic asthma; in the brain in
experimental and clinical forms of encephalitis; and in the
synovium in arthritis (33). In the setting of experimental
atherosclerosis, RANTES is colocalized with cells in athero-
sclerotic lesions(20).Recent studies inkidneyﬁbrosismodels
have indicated a role for RANTES in this process linking it to
local T-cell and macrophage inﬁltration (34). Our ﬁnding
thatAng IIpromotesRANTESexpression in theperivascular
fat might therefore represent an important mechanism for
targeting inﬂammation to this site in hypertension.
As indicated by its name (regulated on activation, nor-
mal T-cell expressed and secreted), RANTES was ﬁrst
identiﬁed in T cells and was considered to be a T-cell-
speciﬁc product (35). However, subsequent studies have
shown that it can be produced by many cells and
contributes to many pathologic processes including can-
cer, allergy, infection, and atherosclerosis (36). While
RANTES can be produced by T cells, in preliminary stud-
ies, we found that vascular levels of RANTES mRNA in-
creased to a similar extent in RAG-12/2 and WT mice
treated with Ang II. This indicates that T cells are not re-
quired for this vascular/AT response and may participate
in an effector phase of this reaction. It is conceivable that
T cells, once localized to the AT, additionally contribute to
tissue RANTES expression in a feed-forward fashion. It is
also of interest that in other preliminary studies we found
that the increase in circulatingCD44high andCD69+ T cells
caused byAng II was similar betweenRANTES2/2 andWT
mice, while the vascular homing of these cells is di-
minished. This indicates that RANTES is not necessary for
T-cell activation by the hypertensive stimulus but that it is
essential for tissue homing of inﬂammatory cells in hy-
pertension and can be a valuable treatment target (37).
Prior studies have shown that high-fat feeding of mice
causes an accumulation of T cells in visceral AT of male
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Figure 7. Effects of met-RANTES on vascular function and perivascular T-cell inﬁltration in Ang II–dependent hypertension. A)
Effect of Ang II–induced hypertension on endothelium-dependent vasodilatation to ACh in aortas of saline (saline) and met-
RANTES-treated (50 mg/kg i.p.) mice (left; n = 5 for each). Relaxations to sodium nitroprusside as measure of non-endothelium-
dependent vasodilatation (right; n = 5 for each). B) Aortic superoxide levels measured by monitoring oxidation of
dihydroethidium to 2-hydroxyethidium using HPLC in control and met-RANTES-treated mice infused for 14 d with buffer
(sham) or Ang II (n = 5). C) Effects of met-RANTES on mean T-cell (CD45+CD3+) inﬁltration in isolated pVAT (minus aorta)
during Ang II–dependent hypertension (n = 5).
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mice (4, 38). This is accompanied by increases in mRNA
andprotein levels of RANTES andCCR5 and is dependent
on the TH1 cytokine IFN-g. Wu et al. (4) have shown that
subcutaneous fat of obese humans have high levels of
T cells, and that these correlate with levels of RANTES and
body mass index. Others have shown that effector T cells
preferentially home to visceral, but not subcutaneous, AT
(39). In this regard, our ﬁndings suggest that Ang II in-
fusion shares some characteristics of fat feeding in pro-
moting AT inﬂammation, with a propensity for targeting
the perivascular fat.
The explanation for the preferential effect of hyper-
tension on inﬂammation in pVAT is unclear. It is possible
that this is due to catecholaminergic stimulation in this
tissue. More than 4 decades ago, Wirsen (40) showed that
AT is highly innervated with sympathetic nerve terminals
and proposed that norepinephrine released from peri-
adventitial nerves in vesselsmight inﬂuence adjacent fat. It
is of interest that islands of BAT, which are highly in-
nervated, arepresent inwhiteATalong theaortaandother
vessels inmice andhumans (41).Although the response of
BAT to Ang II is unknown, sympathetic stimulation pro-
motes both thermogenesis and development of BAT. It is
also possible that reactive oxygen species or other media-
tors releasedby vascular cells diffuse to theadjacent fat cells
and promote expression of molecules such as RANTES,
leading to the inﬂammatory response. It has also been re-
ported that stimulation of the AT2 receptor, which we
found expressed in pVAT, promotes RANTES expression
in glomerular endothelial cells (42). Interestingly, in our
own studies, both AT1 and AT2 receptor expression oc-
curred in the pVATbut was not affected byAng II infusion.
It is therefore possible that Ang II promotes pVAT ex-
pression of RANTES via AT1R or AT2R activation.
Our studies in humans also show a signiﬁcant inverse
relationship between ﬂow-mediated vasodilatation and
serumRANTES levels. Likewise, we found the serum levels
of vWF, an independent marker of endothelial dysfunc-
tion, correlates with serum RANTES. These data suggest
that RANTES might also affect endothelial function in
humans. These translational results need tobe interpreted
with caution because the population studied was hetero-
geneous and exhibited several concomitant factors that
may independently affect RANTES levels and vascular pa-
thology. These include type 2 diabetes, obesity, hypercho-
lesterolemia, smoking, and various medications used by
patients (Table 1). Our patient population exhibited a
high incidence of obesity; Wu et al. (4) have shown that AT
of humans expresses high levels of RANTES and that this
measurecorrelateswith thepresenceofTcells as estimated
by the marker CD3.
In summary, the present study indicates that pVAT
represents a novel site of Ang II–induced inﬂammation
and that it responds differently from other fat deposits.
Ang II–induced hypertension is associated with a strik-
ing increase in T cells and macrophages into pVAT in
both RANTES-dependent and -independent fashions.
RANTES, through regulation of IFN-g-producing T cells,
seems to affect vascular endothelial function but not the
ultimate hypertension caused by Ang II. This pathway
could represent a valuable target for preventionof vascular
complications of hypertension. The accumulation of in-
ﬂammatory cells in the perivascular fat in response to Ang
II might contribute to the enhancement of atherosclerosis
(19) in hypertension. These studies emphasize the com-
plexity of chemokine signaling in AT and the unique role
of pVAT in the modulation of vascular disease.
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